Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Rheumatoid Arthritis
94%
Inflammatory Arthritis
94%
Sarcoidosis
89%
Disease Modifying Antirheumatic Drug
73%
Diseases
59%
Prevalence
44%
Abatacept
44%
Infection
44%
Infliximab
44%
Methotrexate
44%
Biological Product
44%
Tumor Necrosis Factor Inhibitor
40%
Adalimumab
33%
Tofacitinib
33%
Comorbidity
23%
Randomized Clinical Trial
22%
Randomized Controlled Trial
22%
Tumor Necrosis Factor
22%
Placebo
17%
All Cause Mortality
16%
Standardized Mortality Ratio
16%
Lung Disease
15%
Skin Cancer
13%
Mortality Rate
11%
Anakinra
11%
Etanercept
11%
Lung Sarcoidosis
11%
Sarilumab
11%
Golimumab
11%
Rituximab
11%
Skin Disease
11%
Ustekinumab
11%
Observational Study
8%
Disease Severity
8%
Immunology and Microbiology
Inflammatory Arthritis
89%
Disease-Modifying Antirheumatic Drug
59%
Biological Product
44%
Sarcoidosis
44%
Methotrexate
44%
Infliximab
35%
Tofacitinib
26%
Adalimumab
26%
Comorbidity
23%
Tumor Necrosis Factor
17%
TNF Inhibitor
17%
Forced Vital Capacity
17%
Data Synthesis
8%
Arm
8%
Anakinra
8%
Rituximab
8%
Sarilumab
8%
Ustekinumab
8%
Golimumab
8%
Sample Size
8%
Etanercept
8%
Medicine and Dentistry
Cohort Analysis
50%
Prevalence
44%
Sarcoidosis
44%
Disease Modifying Antirheumatic Drug
44%
Rheumatoid Arthritis
44%
Inflammatory Arthritis
44%
Standardized Mortality Ratio
16%
All Cause Mortality
16%
Mortality Rate
11%
Primary Health Care
11%
Disease Severity
8%
Universal Health Care
8%
Socioeconomic Status
8%
Comorbidity
8%
Secondary Care
5%
Cohort Effect
5%
Sex Ratio
5%
